CEREBRAL BLOOD-FLOW IN PATIENTS WITH DEMENTIA OF ALZHEIMERS TYPE

被引：29

作者：

POSTIGLIONE, A

LASSEN, NA

HOLMAN, BL

机构：

[1] Institute of Internal Medicine and Metabolic Diseases, II Facoltà di Medicina e Chirurgia, 2nd Medical School, University of Napoli, Napoli, 80131

[2] Department of Nuclear Medicine/Clinical Physiology, Bispebjerg Hospital, Copenhagen

[3] Department of Radiology, Brigham and Women’S Hospital, Harvard Medical School, Boston, Massachusetts

来源：

AGING-CLINICAL AND EXPERIMENTAL RESEARCH | 1993年 / 5卷 / 01期

关键词：

CEREBRAL BLOOD FLOW; NEURONAL METABOLISM; ALZHEIMERS DISEASE;

D O I：

10.1007/BF03324122

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

In the normal brain as well as in Alzheimer's disease (AD), regional cerebral blood flow (CBF) is coupled to metabolic demand and, therefore, changes in CBF reflect variations in neuronal metabolism. The use of radionuclide techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), provides an accurate assessment of regional functional activity, i.e., CBF and metabolism, and could be very helpful for the differential diagnosis of AD. This disease is characterized by a decrease in global CBF and metabolism. When found, a symmetric bi-parieto-temporal CBF reduction is highly diagnostic for AD, despite the fact that a similar CBF pattern could also be observed in other types of dementia. Many AD patients with parieto-temporal flow reduction also have a diffuse flow reduction in the frontal cortical areas, particularly in advanced stages of the disease. Lateral CBF asymmetry is also very frequent; speech disorders are highly characteristic of left-sided flow reduction, while visuospatial apraxia is dominating in the right-sided cases. In advanced and severe cases of AD, CBF and metabolism tend to be more uniformly reduced throughout the cortex, sparing only the primary visual and sensory-motor cortices. PET and SPECT measurement of brain perfusion and metabolism has added a new dimension to the knowledge of dementia disorders, with a better differential diagnosis between AD and other forms of dementia. The correlation with neuropsychological data has also given new insight into the disease.

引用

页码：19 / 26

页数：8

共 70 条

[1]

Hafner H., The brain disease of aging. Epidemiology and risk factors of senile dementia (Alzheimer), Molecular mechanisms of aging, pp. 2-17, (1990)

[2]

McKahn G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease, Neurology, 34, pp. 939-944, (1984)

[3]

Johnson K.A., Davis K.R., Buonanno F.S., Brady T.J., Rosen J., Growdon J.H., Comparison of Magnetic Resonance and Roengten Ray Computed Tomography in Dementia, Arch. Neurol., 44, pp. 1075-1080, (1987)

[4]

Sandor T., Albert M., Stafford J., Kemper T., Symmetrical and asymmetrical changes in brain tissue with age as measured on CT scans, Neurobiol. Aging, 11, pp. 21-27, (1990)

[5]

Stokely E.M., Sveindottir E., Lassen N.A., Rommer P., A single photon dynamic computer assisted tomograph (DCAT) for imaging brain function in multiple cross sections, J. Comput. Assist. Tomogr., 4, pp. 230-240, (1980)

[6]

Celsis P., Goldman T., Henriksen L., Lassen N.A., A method for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations, J. Comput. Assist. Tomogr., 5, pp. 641-645, (1981)

[7]

Kuhl D.E., Barrio J.R., Huang S.H., Selin C., Ackerman R.F., Lear J.L., Quantifying local cerebral blood flow by N-isopropyl- (1231) iodoamphetamine (IMP) tomography, J. Nucl. Med., 23, pp. 196-203, (1982)

[8]

Hill T.C., Holman B.L., Lovett R., O'Leary D.H., Front D., Magistretti P., Zimmerman R.E., Moore S., Clouse M.E., Wu J.L., Lin T.H., Baldwin R.M., Initial experience with SPECT (single photon computerized tomography) of the brain using n-isopropyl I-123 iodoamphetamine: concise report, J. Nucl. Med., 23, pp. 191-195, (1982)

[9]

Gemmel H.G., Sharp P.F., Evans N.T.S., Besson J.A.O., Lyall D., Smith F.W., Single photon emission tomography with I-123 isopropylamphetamine in Alzheimer’s disease and multiinfarct dementia, Lancet, 2, (1984)

[10]

Johnson K.A., Holman B.L., Rosen J., Nagel S., English R.J., Growdon J.H., Iofetamine I-123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer’s disease, Arch. Intern. Med., 150, pp. 752-756, (1990)

← 1 2 3 4 5 6 7 →